$CRBP insider trading
Over the last 12 months, Corbus Pharmaceuticals Holdings insiders reported 3 buys totaling $126K and 15 sales totaling $1.7M across SEC Form 4 filings. 56% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $126K 3 events
- Sold · 12m
- $1.7M 15 events
- Events · 12m
- 18 Form 4 filings, grouped
- Insiders · 12m
- 9 distinct reporters
- 10b5-1 share
- 56% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 11, 2026 | Saxena Nishant CChief Business Officer · O | ▲ Buy | 2,600 | $9.63 | $25K | +3.5% | — |
| Aug 7, 2026 | Cohen YuvalChief Executive Officer · O·D | ▼ Sale | 17,000 | $10.08 | $171K | -9.8% | plan |
| Aug 7, 2026 | Moran Sean F.Chief Financial Officer · O | ▼ Sale | 12,000 | $10.08 | $121K | -12.4% | plan |
| Jun 10, 2026 | Kung WinstonD | ▼ Sale | 2,026 | $7.91 | $16K | -14.3% | plan |
| Jun 10, 2026 | Altmeyer AnneD | ▼ Sale | 2,412 | $7.91 | $19K | -24.1% | plan |
| Jun 10, 2026 | Jenkins John KennethD | ▼ Sale | 4,800 | $7.91 | $38K | -55.6% | plan |
| Jun 3, 2026 | Saxena Nishant CChief Business Officer · O | ▲ Buy | 9,000 | $7.58 | $68K | +13.6% | — |
| Jun 2, 2026 | Saxena Nishant CChief Business Officer · O | ▲ Buy | 4,500 | $7.33 | $33K | +7.3% | — |
| Mar 2, 2026 | Smethurst DominicChief Medical Officer · O | ▼ Sale | 6,097 | $8.3 | $51K | -6.4% | — |
| Feb 17, 2026 | Hodgson IanChief Operating Officer · O | ▼ Sale | 847 | $7.38 | $6K | -1.6% | — |
| Feb 13, 2026 | Moran Sean F.Chief Financial Officer · O | ▼ Sale | 4,701 | $7.78 | $37K | -4.6% | plan |
| Feb 13, 2026 | Cohen YuvalChief Executive Officer · O·D | ▼ Sale | 13,871 | $7.78 | $108K | -7.4% | plan |
| Feb 3, 2026 | Smethurst DominicChief Medical Officer · O | ▼ Sale | 3,285 | $8.09 | $27K | -3.3% | — |
| Feb 3, 2026 | Hodgson IanChief Operating Officer · O | ▼ Sale | 2,415 | $8.09 | $20K | -4.4% | — |
| Dec 11, 2025 | Cormorant Asset Management, LP10% | ▼ Sale | 30,029 | $11.46 | $344K | -1.3% | indirect |
| Oct 27, 2025 | Cohen YuvalChief Executive Officer · O·D | ▼ Sale | 27,633 | $17.05 | $471K | -16.7% | plan · 2 tranches |
| Oct 24, 2025 | Moran Sean F.Chief Financial Officer · O | ▼ Sale | 12,981 | $17.02 | $221K | -15% | plan |
| Oct 20, 2025 | Altmeyer AnneD | ▼ Sale | 1,060 | $20.5 | $22K | -14.6% | plan |
Every $CRBP filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Corbus Pharmaceuticals Holdings filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $CRBP feed.